drugset / Trial / NCT07006077
Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
The main goal of this clinical trial is to preliminary evaluate the efficacy of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced pancreatic cancer.And the secondary purpose is to evaluate the safety of hV01.
Timeline
- Start
- 2025-05-29
- Primary completion
- 2028-12-31
- Completion
- 2029-03-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hV01 | Unknown | 8e+08 unknown | Other |